A Comparative Study on the Effects of Domperidone, Metoclopramide, Clebopride and Trimebutine on the Gastro-Duodenal Preparation of the Guinea Pig

Jan A.J. SCHUURKES, Ludo F.M. HELEN and Jan M. VAN NUETEN
Department of Pharmacodynamics, Janssen Pharmaceutica Research Laboratories, B-2340 Beerse, Belgium
Accepted June 3, 1985

Abstract—Domperidone (dopamine antagonist), metoclopramide and clebopride (both dopamine antagonists and stimulators of the intramural cholinergic system), and trimebutine (spasmolytic) are used in the treatment of digestive disorders such as dyspepsia or gastritis. Our aim was to compare the effects of these compounds on the isolated intact gastroduodenal preparation of the guinea pig. Domperidone (IC50=10^{-6} M), clebopride (10^{-5} M) and metoclopramide (2\times10^{-5} M) antagonized gastric relaxations induced by dopamine. In contrast with clebopride, domperidone and metoclopramide enhanced the amplitude of gastric contractions, moderately reduced contractile frequency, and enhanced antroduodenal coordination in a dose-dependent manner (EC50 for domperidone 3\times10^{-7} M, for metoclopramide 2\times10^{-6} M). Trimebutine reduced gastric spontaneous activity and antroduodenal coordination. Trimebutine had a direct relaxatory effect on gastric tone (EC50=4\times10^{-6} M). The mechanism of this inhibitory effect remains unknown but our data indicate that it is not mediated via dopamine or opiate receptor subtypes.

Conclusion: domperidone, clebopride, metoclopramide and trimebutine exert distinct and diverse effects on the motility parameters of the gastroduodenal preparation of the guinea pig. These diverging actions may help explain the differences in patients' responsiveness to the treatment of digestive disorders such as dyspepsia or gastritis.

Domperidone is widely used for upper gastrointestinal discomfort, varying from nausea and vomiting to milder dyspeptic symptoms (1). Pharmacologically, domperidone is a selective dopamine antagonist (2, 3). To elucidate the mechanism of action of prokinetic compounds like domperidone, the gastroduodenal preparation of the guinea pig has been studied (2). In this preparation, domperidone was shown to enhance antroduodenal coordination via specific dopamine receptors located on intramural nerves (4). Other prokinetic dopamine antagonists like metoclopramide and clebopride have, in addition to their dopamine antagonistic properties, direct stimulatory effects on the gastrointestinal cholinergic innervation most likely by enhancing the release of acetylcholine (5, 6). Recently, the spasmolytic trimebutine, a compound not interfering with either the cholinergic or dopaminergic system, was tested in dyspeptic patients (7).

The aim of the present study was to compare the motility effects of domperidone, metoclopramide, clebopride and trimebutine on the gastroduodenal preparation of the guinea pig.

Materials and Methods

Pirbright guinea pigs (350–450 g, fasted overnight) of either sex were killed by cervical dislocation. The stomach and the first 10 cm of the duodenum with adhering vasculature were removed for experimentation. The intraluminal contents were removed by repeated washing.
After ligation of the esophagus, the stomach was filled with 20 ml saline and suspended in 200 ml of oxygenated (95% O₂, 5% CO₂) Krebs-Henseleit solution (KCl, 4.7; CaCl₂·2H₂O, 2.5; MgSO₄·7H₂O, 1.2; NaHCO₃, 25.0; KH₂PO₄, 1.2; NaCl, 118.1; glucose, 5.55 mM), maintained at 37°C. The duodenum was cannulated and connected with an ultrasonic transit time transducer (Janssen Scientific Instruments Division) to record changes in intraluminal volume and with a bottle of saline to ensure a constant hydrostatic pressure of 6 cm H₂O. Gastric relaxation, as quantified by incremental changes in gastric volume, was induced pharmacologically by intra-arterial injection of dopamine (Janssen Chimica) (2.6×10⁻⁷ moles) via the left gastric artery in volumes of 50 μl at intervals of 10 min. When reproducible relaxations were obtained, a compound was administered to the bathing solution. Drug effects were followed for 70 min. To correct for the gradual increase in agonist-induced relaxation with time in the control experiments, the control responses (expressed as % of their initial relaxation at t₀) were taken as 100% at each time point: t₀, t₁₀, t₂₀, …, t₇₀. Agonist-induced relaxations in the presence of a compound (in % of initial value) were then individually calculated as % of the value at the corresponding time point in the control experiments. Dose-response curves were made by plotting the percentage inhibition of agonist-induced relaxation against the concentration of a compound.

Spontaneous phasic activity was always present on the stomach and recorded as rhythmic changes in gastric volume. Gastric peristaltic waves either stopped at the pylorus or were propagated to the duodenum. The passage of the antral wave to the duodenum was marked on the recording paper. Antroduodenal coordination was quantified as the relative number of antral waves that were propagated to the duodenum, i.e., that were followed by a duodenal contraction in the second quarter of the rhythmic pen deflection. Autonomous duodenal contractions (not linked to the antral wave) were observed only exceptionally and therefore not taken into account. After a 30-min stabilization period, domperidone (Janssen), clebopride (Almirall), metoclopramide (Delagrange) or trimebutine (Jouveinal) were added to the bath solution at varying concentrations. Drug effects were followed for 30 min. The effects of trimebutine were also assessed in the presence of domperidone (6×10⁻⁶ M) or naloxone (Endo) (4.5×10⁻⁷ M). Three parameters were determined: 1) antral contractile amplitude, expressed as ml of expelled volume; 2) antral frequency, measured as number of contractions per minute; and 3) % antroduodenal coordination. Results were statistically evaluated with Student's two-tailed t-test for paired or unpaired observations (P<0.05).

Results

Intra-arterial injection of dopamine induced reproducible relaxations of the gastro-duodenal preparation (Fig. 1). These relaxations could be inhibited upon administration of domperidone in the bathing solution. The maximal effect of domperidone was reached after 50 min (Fig. 1). Interestingly, as demonstrated in Fig. 1, domperidone also regularized the spontaneous motor activity and enhanced its amplitude already within 10 min after its administration. Clebopride (Fig. 1) and metoclopramide also effectively antagonized the dopamine-induced relaxations. In contrast with domperidone, their effects peaked at 10 min.

The direct effects of the test compounds on spontaneous contractile activity and tone are better demonstrated at higher paper speed (Fig. 2). Domperidone enhanced the amplitude of the antral contractions and induced duodenal contractions to occur at the same frequency as the antral waves, i.e., domperidone induced a coordinated pattern of antroduodenal motility (Fig. 2). Similar findings were obtained with metoclopramide but only in some (4/6 at 1.2×10⁻⁶ M) experiments with clebopride. In contrast to the latter drugs, trimebutine (Fig. 2) reduced both the tone of the preparation and the amplitude of the spontaneous gastric contractions. In preparations with duodenal activity, trimebutine inhibited the occurrence of these contractions. The gastric relaxation induced by trimebutine persisted throughout
the experiment (Fig. 2). It could not be prevented by domperidone ($6 \times 10^{-6}$ M) nor reversed by naloxone ($4.5 \times 10^{-7}$ M). This effect was dose-dependent (Fig. 3) with an EC$_{50}$-value of $3.6 \times 10^{-6}$ M [lower limit (LL) = $2.4 \times 10^{-6}$ M; upper limit (UL) = $5.5 \times 10^{-6}$ M]. Due to these intrinsic relaxatory effects of trimebutine, its effect on dopamine-induced relaxation could not be tested.

Dose-response studies revealed that domperidone was most effective in antagonizing gastric relaxations induced by dopamine (Fig. 4). Its IC$_{50}$-value was $1.0 \times 10^{-6}$ M (LL = $0.6 \times 10^{-6}$ M, UL = $1.6 \times 10^{-6}$ M).
In this regard, domperidone was 10 and 17 times more potent than clebopride and metoclopramide, respectively. The IC50 value for clebopride was $1.0 \times 10^{-5}$ M ($LL=5.7 \times 10^{-6}$ M, $UL=1.7 \times 10^{-5}$ M); for metoclopramide $1.7 \times 10^{-5}$ M ($LL=1.0 \times 10^{-5}$ M, $UL=3.0 \times 10^{-5}$ M).

Fig. 2. Effects of domperidone (A) and trimbutine (B) on spontaneous rhythmic activity and basal tone in the gastroduodenal preparation of the guinea pig. A=antral contractile activity, D=occurrence of a coordinated duodenal contraction.

Both domperidone and metoclopramide significantly enhanced gastric contractile amplitude (Fig. 5), but their effects were only observed at a single concentration. The effective concentration of domperidone appeared 34 times lower than that needed for metoclopramide. Clebopride did not enhance the amplitude significantly. Trimbutine reduced contractile amplitude (Figs. 1 and 5). At the optimal concentrations tested, only domperidone and metoclopramide had significant effects, i.e., reduced the frequency of the gastric contractions (Fig. 6).

Both domperidone (Fig. 2) and metoclopramide enhanced antroduodenal coordination in a dose-dependent manner (Fig. 7). The EC50 value for domperidone was $2.8 \times 10^{-7}$ M ($LL=1.6 \times 10^{-7}$ M, $UL=4.7 \times 10^{-7}$ M). In this regard, domperidone was 160 times more potent than metoclopramide, its EC50 value being $2.2 \times 10^{-5}$ M ($LL=1.7 \times 10^{-5}$ M, $UL=2.7 \times 10^{-5}$ M). Clebopride moderately enhanced antroduodenal coordination (Fig. 7), but only at $1.2 \times 10^{-6}$ M. From this
concentration upwards, the compound induced in some experiments (3/7 at 4.9x10^{-6} M; 5/6 at 2.0x10^{-5} M) a short-lasting gastric relaxation and inhibition of contractile amplitude. Trimebutine significantly reduced antroduodenal coordination (Fig. 7). The EC50-value for this effect of trimebutine was 5.5x10^{-6} M (LL=3.1x10^{-6} M, UL=9.7x10^{-6} M).

Discussion

These results clearly indicate that the four test compounds exerted different effects on the gastroduodenal preparation of the guinea pig.

Domperidone antagonized the relaxatory effects of dopamine at low concentrations (2, 8). In this respect, domperidone was more potent than either clebopride or metoclopramide. The potency order of these compounds is similar to that found for their respective binding affinity to striatal dopamine receptors in vitro (3, 9) as well as for their ED50-values as antagonist against apomorphine-induced vomiting (dopamine receptor-mediated) in conscious dogs (10). The
observation that domperidone reached its optimal effect after a longer incubation period than metoclopramide is in agreement with experimental data indicating a rapid but short-lasting action of the latter drug (11).

Trimebutine was not tested against dopamine-induced gastric relaxations since the drug itself had a pronounced inhibitory effect on gastric tone; it induced a dose-dependent gastric relaxation. The EC50-value for this spasmolytic effect was similar to the EC50-value for the inhibition of antroduodenal coordination by trimebutine. These concentrations as well as those at which trimebutine reduced the amplitude of the gastric contractions in our intact gastroduodenal preparation were similar to those reported for antral strips of the guinea pig (10⁻⁶-10⁻⁴ M) (12, 13). This inhibitory action was not mediated via α- or β-adrenergic receptors (13) and as our results with domperidone indicate, also not via dopaminergic receptors. The insensitivity of the effect of trimebutine to naloxone indicates that in our model, opiate receptors are not involved in its action, in contrast to its effect on intestinal motility in the conscious dog (14).

Domperidone appeared most effective in
stimulating rhythmic activity of the preparation. The concentrations needed to enhance antral contractile amplitude and to reduce frequency were 34 times below those needed for metoclopramide. Clebopride did not affect amplitude or frequency of the gastric waves, but it did enhance antroduodenal coordination at $1.2 \times 10^{-6}$ M. However, when the concentration was increased, this effect was lost. In contrast, both domperidone and metoclopramide enhanced antroduodenal coordination in a dose-dependent manner, domperidone being 160 times as potent as metoclopramide. The broad effective dose range of domperidone and metoclopramide on antroduodenal coordination contrasts with the finding that their effects on gastric contractile activity were limited to a single concentration, indicating that the effects of the compounds on antroduodenal coordination are not caused by an effect on gastric contractile amplitude or frequency.

Clebopride is more effective than metoclopramide against dopamine-induced gastric relaxations, whereas metoclopramide is more effective on antroduodenal coordination. This paradox between two chemically closely related compounds remains to be solved. The relatively small effect of clebopride on antroduodenal coordination cannot be explained by its serotoninergic blocking properties (6) since cisapride, a chemically-related compound (without dopamine-antagonistic properties) but also effective in antagonizing contractile responses to serotonin (15), does enhance antroduodenal coordination in this preparation in a dose-dependent manner (9, 16).

The findings with these four compounds may help to explain their effects in dyspepsia. Trimebutine is indicated in painful dyspepsia of spastic origin (17) in which the question remains whether either the upper gastrointestinal tract or the colon is causing the discomfort (18). In a double blind cross-over study, domperidone proved superior over trimebutine in functional dyspepsia (7). Domperidone and also metoclopramide have quite opposite effects to trimebutine in that they stimulate antroduodenal motility while moderately reducing gastric contractile frequency. A similar reduction of gastric frequency by domperidone was also observed in conscious dogs (11). Cooke and Stember (19) showed that gastric emptying rate was optimal at a frequency of about 4 contractions per min in the dog. Therefore, a moderate reduction in contractile frequency may be important in man as well, in cases where gastric dysrhythmia (20) is the underlying cause of the dyspeptic complaint.

In conclusion: domperidone, clebopride, metoclopramide and trimebutine showed distinct effects on the gastroduodenal preparation of the guinea pig. Whereas trimebutine inhibited gastric tone, contractile amplitude and antroduodenal coordination as well, domperidone (low concentrations) and metoclopramide (high concentrations) enhanced amplitude and antroduodenal coordination but slightly reduced contractile frequency. Clebopride was relatively ineffective in enhancing gastric rhythmic activity but did antagonize the inhibitory action of dopamine on gastric tone as did domperidone and metoclopramide. These diverging actions may help explain the differences in patients' responsiveness to the treatment of digestive disorders such as dyspepsia or gastritis.

Acknowledgement: The authors are indebted to Drs. A.J. Reyntjens, W.J. Janssens and G.J.J.M. Vanderstichele for critical evaluation of the manuscript, to Mr. W.J.E. De Ridder for statistical analysis, to Mr. C.A.M. Van der Eycken for literature retrieval, Mr. J.M. Van Mierlo for preparing the illustrations, and Mrs. E.C.J. Wouters for secretarial assistance.

References
1 Brogden, R.N., Carmine, A.A., Heel, R.C., Speight, T.M. and Avery, G.S.: Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24, 360–400 (1982)
2 Van Nueten, J.M., Ennis, C., Helsen, L., Laduron, P.M. and Janssen, P.A.J.: Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone. Life Sci. 23, 453–458 (1978)
3 Laduron, P.M. and Leysen, J.E.: Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem. Pharmacol. 28, 2161–2165 (1979)
4 Schuurkes, J.A.J. and Van Nueten, J.M.:
Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites. Scand. J. Gastroenterol. 19, Supp. 96, 101–110 (1984)

5 Kilbinger, H., Kruel, R., Pfeuffer-Friederich, I. and Wessler, I.: The effects of metoclopramide on acetylcholine release and on smooth muscle response in the isolated guinea pig ileum. Naunyn Schmiedebergs Arch. Pharmacol. 319, 231–238 (1982)

6 Roberts, D.J.: The pharmacological basis of the therapeutic activity of cibopride and related substituted benzamides. Current Ther. Res. 31, S1–S44 (1982)

7 Vuilleul, J.P. and Laverdant, C.: Etude comparée du dompéridone et de la trimébutine dans le traitement de la dyspepsie fonctionnelle. Étude croisée en double insu. Lyon Médicale 253, 43–48 (1985)

8 Van Nueten, J.M. and Janssen, P.A.J.: Effect of domperidone on gastric relaxation caused by dopamine, secretin, 5-hydroxytryptamine, substance P, and adenosine triphosphate. In Gastrointestinal Motility, Edited by Christensen, J., p. 225–231, Raven Press, New York (1980)

9 Van Nueten, J.M., Leysen, J.E., Niemegeers, C.J.E. and Schuurkes, J.A.J.: Cholinergic vs anti-dopaminergic properties of prokinetic substituted benzamides with gastrointestinal prokinetic activity. Gastroenterology (Abstract) 88, 1623 (1980)

10 Niemegeers, C.J.E.: Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berlin) 78, 210–213 (1982)

11 Shuto, K., Shiozaki, S., Kojima, T. and Tanaka, M.: Effects of KW-5338 (domperidone) on gastric motility. J. Pharmacobiody. 3, 715–719 (1980)

12 Furukawa, K. and Kimoto, Y.: Effects of trimbutine maleate (TM-906) on electrical and mechanical activities of smooth muscles of the guinea-pig stomach. Japan. J. Pharmacol. 35, 307–317 (1984)

13 Takenaga, H., Magaribuchi, T. and Tamaki, H.: Effects of trimbutine maleate (TM-906) on the spontaneous contraction of the isolated guinea pig stomach. Folia Pharmacol. Japon. 80, 163–168 (1982) (Abs. in English)

14 Fioramonti, J., Fargeas, M.J. and Bueno, L.: The involvement of opiate receptors in the effects of trimbutine on intestinal motility in the conscious dog. J. Pharm. Pharmacol. 36, 618–621 (1984)

15 Schuurkes, J.A.J. and Van Nueten, J.M.: Evidence against a serotonergic mechanism for the motility stimulating properties of cisapride. Gastroenterology (Abstract) 88, 1577 (1985)

16 Van Nueten, J.M., Van Daele, P.G.H., Reutjens, A.J., Janssen, P.A.J. and Schuurkes, J.A.J.: Gastrointestinal motility stimulating properties of cisapride, a non-antidopaminergic non-cholinergic compound. In Gastrointestinal Motility, Edited by Roman, C.I., p. 513–520, MTP Press Ltd., Lancaster and Boston (1984)

17 Bonzi, G., Reguzzoni, G., Rocca, F. and Negri, L.: IL DA 3177, nuovo spasмолitico di sintesi, nella terapia degli stati spastici e discinetici dell’apparato digerente. Studio clinico controllato doppio cieco. Cl. Terap. 89, 187–196 (1979)

18 Lüttecke, K.: A three-part controlled study of trimbutine in the treatment of irritable colon syndrome. Curr. Med. Res. Opin. 6, 437–443 (1980)

19 Cooke, A.R. and Stemper, T.J.: The function of the antrum and pylorus in controlling emptying of liquid meals. In Proceedings of the Fifth International Symposium on Gastrointestinal Motility, Edited by Vamtrappen, G., p. 278–283, Typoff Press, Herentals (1976)

20 Chey, W.Y., You, C.H., Lee, K.Y. and Menguy, R.: Gastric dysrhythmia: clinical aspects. In Functional Disorders of the Digestive Tract, Edited by Chey, W.Y., p. 175–181, Raven Press, New York (1983)